New research on the cancer-fighting potential of vitamin C has made the pages of the peer-reviewed journal Science Translational Medicine. A big team of researchers from the University of Kansas reportedly tested the effects of vitamin C given in high doses intravenously on a group of human subjects and found that it effectively eradicates cancer cells while leaving healthy cells intact.
Building upon earlier research pioneered in the 1970s by the late Linus Pauling, a chemist from Oregon State University who today is recognized as the world’s foremost proponent of therapeutic vitamin C, the new research involved injecting high doses of vitamin C into human ovarian cells. The tests were conducted in vitro in a lab, as well as directly in both mice and a group of 22 human subjects.
I’m really excited about this post because I’m sharing some really cool stuff about Vitamin C that many people do not know. Or maybe I’m wrong and everyone already knows this but me… We’ll see.
This is a powerful anti-cancer protocol and even if you don’t have cancer, you can use this method to determine how much toxic stress is going on inside your body and how high doses of Vitamin C could dramatically improve your health.
Ok so we all now that Vitamin C (ascorbic acid) is good for you right?
The body doesn’t produce it, so it has to come from food.
According to BBC News, the tests showed favorable results in all three models, as the vitamin C effectively targeted the ovarian cancer cells while avoiding healthy cells. The benefits of high-dose vitamin C were also observed in conjunction with conventional chemotherapy treatments, which destroy all cells, both healthy and malignant, eventually leading to patient death.
“Patients are looking for safe and low-cost choices in their management of cancer,” stated Dr. Jeanne Drisko, a co-author of the study, to BBC Newsconcerning the findings. “Intravenous vitamin C has that potential based on our basic science research and early clinical data.”
Researchers admit more human trials on intravenous vitamin C unlikely because drug companies cannot patent vitamins.
The next step for this type of research would typically involve applying these same parameters in a large-scale clinical human trial to see if they can be replicated and confirmed. While this new study is admittedly convincing on its own, the hurdles to gaining widespread acceptance of its findings include replicating them across a much larger human sample size.
But this may never actually take place. And the reason, says the research team, is that such trials require major funding that typically comes from pharmaceutical companies interested in developing a patented drug. Drug companies, in other words, are hardly interesting in promoting the medicinal benefits of natural substances like vitamin C, which stands to decimate the multibillion-dollar conventional cancer industry if word gets out about its benefits.
“Because vitamin C has no patent potential, its development will not be supported by pharmaceutical companies,” says Qi Chen, lead author of the new study. “We believe that the time has arrived for research agencies to vigorously support thoughtful and meticulous clinical trials with intravenous vitamin C.”